<SEC-DOCUMENT>0001781002-24-000050.txt : 20241007
<SEC-HEADER>0001781002-24-000050.hdr.sgml : 20241007
<ACCEPTANCE-DATETIME>20241007170734
ACCESSION NUMBER:		0001781002-24-000050
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20241007

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cue Biopharma, Inc.
		CENTRAL INDEX KEY:			0001645460
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				473324577
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-90232
		FILM NUMBER:		241358561

	BUSINESS ADDRESS:	
		STREET 1:		40 GUEST STREET
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02135
		BUSINESS PHONE:		617-949-2680

	MAIL ADDRESS:	
		STREET 1:		40 GUEST STREET
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02135

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Imagen Biopharma, Inc.
		DATE OF NAME CHANGE:	20150617

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Bleichroeder LP
		CENTRAL INDEX KEY:			0001781002
		ORGANIZATION NAME:           	
		IRS NUMBER:				842006600
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		1345 AVENUE OF THE AMERICAS
		STREET 2:		47TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10105
		BUSINESS PHONE:		917-769-2999

	MAIL ADDRESS:	
		STREET 1:		1345 AVENUE OF THE AMERICAS
		STREET 2:		47TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10105
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><!-- EDGARfilingagent.com Schedule 13D/G Online Workstation (https://schedule13d.com) --><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
<headerData>
	<submissionType>SCHEDULE 13G/A</submissionType>
	<previousAccessionNumber>0001781002-24-000025</previousAccessionNumber>
	<filerInfo>
		<filer>
			<filerCredentials>
				<cik>0001781002</cik>
				<ccc>XXXXXXXX</ccc>
			</filerCredentials>
		</filer>
		<liveTestFlag>LIVE</liveTestFlag>



	</filerInfo>
</headerData>
<!-- Start Form -->
  <formData>
<!-- Issuer Cover Page-->
    <coverPageHeader>
		<amendmentNo>1</amendmentNo>
      <securitiesClassTitle>Common Stock, par value $0.001 per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>09/30/2024</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001645460</issuerCik>
        <issuerName>Cue Biopharma, Inc.</issuerName>
        <issuerCusip>22978P106</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>40 Guest Street</com:street1>
          <com:city>Boston</com:city>
          <com:stateOrCountry>MA</com:stateOrCountry>
          <com:zipCode>02135</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(b)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
<!-- Reporting Persons Cover Page -->
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Bleichroeder LP</reportingPersonName>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>6127662</soleVotingPower>
        <sharedVotingPower>0</sharedVotingPower>
        <soleDispositivePower>6127662</soleDispositivePower>
        <sharedDispositivePower>0</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>6127662</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.99</classPercent>
      <typeOfReportingPerson>IA</typeOfReportingPerson>
      <comments>Relating to item 11 on this page: Based on 60,207,717 shares reported by the Issuer to be outstanding plus 1,130,422 shares of Common Stock underlying warrants held by the Reporting Persons</comments>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>Bleichroeder Holdings LLC</reportingPersonName>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>6127662</soleVotingPower>
        <sharedVotingPower>0</sharedVotingPower>
        <soleDispositivePower>6127662</soleDispositivePower>
        <sharedDispositivePower>0</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>6127662</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.99</classPercent>
      <typeOfReportingPerson>HC</typeOfReportingPerson>
      <comments>Relating to item 11 on this page: Based on 60,207,717 shares reported by the Issuer to be outstanding plus 1,130,422 shares of Common Stock underlying warrants held by the Reporting Persons</comments>
    </coverPageHeaderReportingPersonDetails>
<!-- Items -->
    <items>
      <item1>
        <issuerName>Cue Biopharma, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>40 Guest Street, Boston, MA  02135</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>Bleichroeder Holdings LLC
Bleichroeder LP</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>1345 Avenue of the Americas, 47th Floor
New York, NY 10105</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Delaware, USA</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>N</notApplicableFlag>
      <typeOfPersonFiling>IA</typeOfPersonFiling>
      <typeOfPersonFiling>HC</typeOfPersonFiling>
      </item3>
      <item4>
        <amountBeneficiallyOwned>See cover page.</amountBeneficiallyOwned>
        <classPercent>See cover page.</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>See cover page.</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>See cover page.</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>See cover page.</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>See cover page.</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
        <classOwnership5PercentOrLess>N</classOwnership5PercentOrLess>
      </item5>
      <item6>
        <notApplicableFlag>N</notApplicableFlag>
        <ownershipMoreThan5PercentOnBehalfOfAnotherPerson>Bleichroeder LP ("Bleichroeder"), an investment adviser registered under Section 203 of the Investment Advisers Act of 1940, is deemed to be the beneficial owner of 6,127,662 shares, or 9.99%, of the common stock ("Common Stock") reported by the Issuer as outstanding. Bleichroeder is the beneficial owner of Common Stock, warrants with a 4.99% limit on the exercise of such warrants, warrants with a 9.99% limit on the exercise such such warrants, and pre-funded warrants with a 9.99% limit on the exercise such such warrants. If there was no 4.99% limit on the exercise of certain warrants, nor a 9.99% limit on the exercise of certain warrants and and pre-funded warrants, Bleichroeder would be deemed to be the beneficial owner of 4,997,240 shares of Common Stock, 306,278 shares of Common Stock issuable upon exercise of the warrants subject to a 4.99% limit, 1,250,000 shares of Common Stock issuable upon exercise of the warrants subject to a 9.99% limit,  and 2,964,366 shares of Common Stock issuable upon exercise of the pre-funded warrants subject to a 9.99% limit, representing 14.7% of the outstanding shares of Common Stock. Clients of Bleichroeder have the right to receive and the ultimate power to direct the receipt of dividends from, or the proceeds of the sale of, such securities.</ownershipMoreThan5PercentOnBehalfOfAnotherPerson>
      </item6>
      <item7>
        <notApplicableFlag>N</notApplicableFlag>
        <subsidiaryIdentificationAndClassification>See exhibit 99.1</subsidiaryIdentificationAndClassification>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
	<!-- Exhibit Information -->
	<exhibitInfo>Exhibit 99.1: Subsidiary Information</exhibitInfo>
	<!-- Signature -->
    <signatureInformation>
      <reportingPersonName>Bleichroeder LP</reportingPersonName>
      <signatureDetails>
        <signature>Michael M. Kellen</signature>
        <title>Chairman And CO-CEO</title>
        <date>10/07/2024</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Bleichroeder Holdings LLC</reportingPersonName>
      <signatureDetails>
        <signature>Michael M. Kellen</signature>
        <title>Chairman And CO-CEO</title>
        <date>10/07/2024</date>
      </signatureDetails>
    </signatureInformation>
	</formData>

</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>SUBSIDIARY INFORMATION (322)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; text-align: center; margin-bottom: 0">Exhibit 99.1</P>
<P STYLE="font: 10pt Times New Roman,serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0">The identity and the Item 3 classification of the relevant subsidiary is: Bleichroeder LP, which is an Investment Adviser in accordance with Rule 13d-1(b)(1)(ii)(E).</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
